Ohno Hitoshi, Ishikawa Takayuki, Kitajima Hiroyuki, Nomura Shosaku, Suzuki Takayo, Konishi Hiroshi, Ohno Yoichiro, Onishi Rie, Konaka Yoshiteru, Arima Nobuyoshi, Doi Shoichi, Nasu Kaori, Takahashi Takayuki, Tsudo Mitsuru, Fukuhara Shirou, Uchiyama Takashi
First Division, Department of Internal Medicine, Faculty of Medicine, Kyoto University, Kyoto.
Rinsho Ketsueki. 2002 Mar;43(3):170-5.
A multi-center series of 117 patients with malignant lymphoma were analyzed to evaluate the clinical significance of soluble interleukin-2 receptor alpha chain (sIL-2R alpha). The initial levels of sIL-2R alpha ranged from 277 U/ml to 22,800 U/ml with a mean level of 3,451 +/- 4,268 U/ml and a median level of 1,600 U/ml. The sIL-2R alpha levels of the diffuse lymphoma/intermediate-grade subtypes defined by the LSG classification/Working Formulation were higher than those of the follicular lymphoma/low-grade subtypes. There was a tendency for B-cell lymphomas to show higher sIL-2R alpha levels than T-cell lymphomas. The sIL-2R alpha level was correlated with the Ann Arbor clinical stage (I, II versus III, IV), presence or absence of B symptoms, and performance status (0, 1 versus 2, 3, 4) of the patients. The sIL-2R alpha levels were in good accordance with the four risk groups defined by the International Prognostic Indices. Of 21 patients whose tumor burden was serially measured, the coefficients of correlation between sIL-2R alpha and tumor mass were > 0.6 in 18 cases. Sixty-two patients achieved complete remission (CR) during the study; the initial and minimum sIL-2R alpha levels were lower than those of the non-CR patients. This study confirmed that sIL-2R alpha is a convenient and useful marker in the management of malignant lymphoma.
对117例恶性淋巴瘤患者的多中心系列研究进行分析，以评估可溶性白细胞介素-2受体α链（sIL-2Rα）的临床意义。sIL-2Rα的初始水平在277 U/ml至22,800 U/ml之间，平均水平为3,451±4,268 U/ml，中位数水平为1,600 U/ml。根据LSG分类/工作方案定义的弥漫性淋巴瘤/中等级别亚型的sIL-2Rα水平高于滤泡性淋巴瘤/低级别亚型。B细胞淋巴瘤的sIL-2Rα水平有高于T细胞淋巴瘤的趋势。sIL-2Rα水平与患者的Ann Arbor临床分期（I、II期与III、IV期）、有无B症状以及体能状态（0、1级与2、3、4级）相关。sIL-2Rα水平与国际预后指数定义的四个风险组高度一致。在21例肿瘤负荷被连续测量的患者中，18例sIL-2Rα与肿瘤质量之间的相关系数>0.6。62例患者在研究期间实现完全缓解（CR）；初始和最低sIL-2Rα水平低于未达到CR的患者。本研究证实sIL-2Rα是恶性淋巴瘤管理中一种方便且有用的标志物。
